new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)



  

Immunomedics Inc patents

Bulk PDF Downloads
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors




Search recent News Headlines: Immunomedics Inc-related news headlines
Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
09/08/16Antibody-sn-38 immunoconjugates with a cl2a linker
09/08/16Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
09/01/16Delivery system for cytotoxic drugs by bispecific antibody pretargeting
09/01/16Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
08/04/16Immunoconjugates with an intracellularly-cleavable linkage
07/14/16Radiosensitivity of fluorophores and use of radioprotective agents for dual-modality imaging
07/07/16Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
06/16/16Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
05/12/16Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
05/12/16Chimeric and humanized anti-histone antibodies
05/05/16Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
04/07/16Neoadjuvant use of antibody-drug conjugates
03/31/16Anti-mucin antibodies for early detection and treatment of pancreatic cancer
03/31/16Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
03/24/16Immunoconjugates with an intracellularly-cleavable linkage
03/10/16Detection of early-stage pancreatic adenocarcinoma
03/03/16Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells
02/18/16Methods and compositions for improved labeling of targeting peptides
02/11/16Immunotherapy of autoimmune disorders using antibodies which target b-cells
02/04/16Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
02/04/16Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
02/04/16Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
01/28/16Humanized anti-hla-dr antibodies
01/07/16Crosslinking of cd22 by epratuzumab triggers bcr signaling and caspase-dependent apoptosis in hematopoietic cancer cells
12/24/15Antibody-drug conjugates and uses thereof
12/24/15Anti-histone therapy for vascular necrosis in severe glomerulonephritis
12/03/15Class i anti-cea antibodies and uses thereof
12/03/15Humanized anti-cd22 antibody
11/12/15Anti-mucin antibodies for early detection and treatment of pancreatic cancer
11/05/15Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
10/29/15Antibody-sn-38 immunoconjugates with a cl2a linker
10/29/15Anthracycline-antibody conjugates for cancer therapy
10/29/15Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
10/08/15Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
09/10/15Anti-cd19 antibodies
08/27/15Humanized rfb4 anti-cd22 antibody
08/13/15Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
08/06/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
08/06/15Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
07/23/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
07/23/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
07/16/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
07/16/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
07/16/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
07/16/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
07/16/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
07/16/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
07/16/15Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
07/02/15Immunoconjugates with an intracellularly-cleavable linkage
07/02/15Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
06/25/15Immunoconjugates with an intracellularly-cleavable linkage
06/25/15Immunoconjugates with an intracellularly-cleavable linkage
06/18/15Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
06/18/15Anti-mucin antibodies for early detection and treatment of pancreatic cancer
06/18/15Humanized l243 antibodies
06/18/15Anti-cd74 immunoconjugates and methods of use
06/04/15Chimeric and humanized anti-histone antibodies
05/14/15Anti-pancreatic cancer antibodies
05/07/15Humanized anti-ceacam5 antibody and uses thereof
04/23/15Class i anti-cea antibodies and uses thereof
04/02/15Anthracycline-antibody conjugates for cancer therapy
03/26/15Dye conjugated peptides for fluorescent imaging
02/26/15Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
02/05/15Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
01/15/15Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.
12/25/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
12/25/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
12/25/14Anti-trop-2 antibody-drug conjugates and uses thereof
12/18/14Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
09/25/14Immunoconjugates with an intracellularly-cleavable linkage
09/25/14Rs7 antibodies
08/21/14Chimeric and humanized anti-histone antibodies
08/14/14Humanized anti-hla-dr antibodies
08/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
08/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
08/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
08/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
08/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
07/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
07/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.
06/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
06/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
06/05/14Anthracycline-antibody conjugates for cancer therapy
05/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
05/22/14Humanized l243 antibodies
05/01/14Rs7 antibodies
04/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
04/24/14Anti-cd19 antibodies
04/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
04/10/14Camptothecin-binding moiety conjugates
03/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
03/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
03/20/14Class i anti-cea antibodies and uses thereof
02/27/14Immunoconjugates with an intracellularly-cleavable linkage
02/13/14Antibody therapy
02/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
02/06/14Anti-pancreatic cancer antibodies
02/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
02/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
01/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
01/16/14Anti-cd19 antibodies
01/02/14Immunoconjugates with an intracellularly-cleavable linkage
11/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
11/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
08/22/13Immunoconjugates with an intracellularly-cleavable linkage
08/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
08/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
07/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
07/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
07/04/13Anti-cd74 immunoconjugates and methods of use
07/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
07/04/13Anthracycline-antibody conjugates for cancer therapy
06/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
06/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
06/20/13Antibody therapy
06/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
06/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
05/16/13Anti-cd19 antibodies
05/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
04/18/13Anti-cd74 immunoconjugates and methods
Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.
04/11/13Immunoconjugates with an intracellularly-cleavable linkage
03/28/13Structural variants of antibodies for improved therapeutic characteristics
03/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
03/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
03/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
03/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
02/14/13Dye conjugated peptides for fluorescent imaging
02/07/13Class i anti-cea antibodies and uses thereof
12/27/12Camptothecin-binding moiety conjugates
12/27/12Immunoconjugates with an intracellularly-cleavable linkage
12/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
11/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
11/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
09/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
08/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
08/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
07/26/12Anti-cd19 antibodies
07/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
07/19/12Therapeutic using a bispecific antibody
06/14/12Fusion proteins containing recombinant cytotoxic rnases
06/07/12Rs7 antibodies
06/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
05/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
05/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
05/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
04/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
04/05/12Immunoconjugates with an intracellularly-cleavable linkage
03/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
03/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
02/16/12Antibody therapy
Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.
02/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
02/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
12/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
12/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
12/01/11Immunoconjugates with an intracellularly-cleavable linkage
11/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
11/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
11/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
10/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
10/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
10/06/11Internalizing anti-cd74 antibodies and methods of use
09/29/11Structural variants of antibodies for improved therapeutic characteristics
09/29/11Methods for protein expression in mammalian cells in serum-free medium
09/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
09/15/11Multivalent carriers of bi-specific antibodies
08/11/11Internalizing anti-cd74 antibodies and methods of use
08/04/11Antibody therapy
08/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
07/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
07/07/11Detection of early-stage pancreatic adenocarcinoma
07/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
05/19/11Methods and compositions for administering therapeutic and diagnostic agents
05/19/11Method of treating immune disease using b-cell antibodies
05/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
03/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
03/24/11Anti-cd74 immunoconjugates and methods
03/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
03/17/11Class i anti-cea antibodies and uses thereof
03/03/11Anti-cd19 antibodies
12/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
11/11/10Internalizing anti-cd74 antibodies and methods of use
10/28/10Anti-cd74 immunoconjugates and methods of use
10/21/10Anti-cd74 immunoconjugates and methods of use
10/21/10Internalizing anti-cd74 antibodies and methods of use
09/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
09/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
09/02/10Antibody therapy
09/02/10Rs7 antibodies
08/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
08/12/10D-amino acid peptides
08/05/10Humanized anti-hla-dr antibodies
08/05/10Humanized l243 antibodies
08/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
07/29/10Novel strategies for improved cancer vaccines
06/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
06/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
06/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
04/29/10Immunoconjugates with an intracellularly-cleavable linkage
03/25/10Anthracycline-antibody conjugates for cancer therapy
03/18/10Anti-cd19 antibodies
02/18/10Structural variants of antibodies for improved therapeutic characteristics
02/11/10Structural variants of antibodies for improved therapeutic characteristics
01/21/10Camptothecin-binding moiety conjugates
01/21/10Internalizing anti-cd74 antibodies and methods of use
01/14/10Production and use of novel peptide-based agents with bispecific antibodies
01/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
12/10/09Anti-pancreatic cancer antibodies
12/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
11/26/09Immunoconjugates with an intracellularly-cleavable linkage
11/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
11/05/09Bispecific antibody point mutations for enhancing rate of clearance
10/08/09Multivalent carriers of bi-specific antibodies
10/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
10/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
10/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
10/01/09Fusion proteins containing recombinant cytotoxic rnases
09/24/09Methods and compositions for administering therapeutic and diagnostic agents
09/24/09Humanized antibodies and methods of humanizing antibodies
07/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
06/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
06/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
04/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
04/09/09Antibody therapy
01/21/10Internalizing anti-cd74 antibodies and methods of use
01/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';